What the new CDC Opioid Prescribing Guidelines mean for your Myositis pain
, , Featured, Myositis Treatments, News
2022 CDC guidelines look to rectify the mistakes made in the 2016 Guidelines that led MSU to a survey...
IVIg Proves Effective for Dermatomyositis in Phase 3 Trial
, , Dermatomyositis, Featured, Myositis Treatments
The study provided efficacy data for Octagam 10%, which was approved for dermatomyositis by the US Food and Drug...
Stephen Moore, a Neuroscientist living with Dermatomyositis joined MSU's Patient-Centered Research Team. His passion lies in advancing research efforts...
Please join us for a webinar about the new VALOR study. The purpose of the VALOR Study is to...
Join us for the 4th Annual Myositis Empower Walk in memory of Robert Landman. Join us in person at...
Co-authors of “Pain profile and opioid medication use in patients with idiopathic inflammatory myopathies”, published in Rheumatology discuss the...
MSU is attending the 2022 Global Conference on Myositis in Prague and will be represented in two (2) scientific...
Kezar Announces Topline Results from the PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
Pain profile and opioid medication use in patients with idiopathic inflammatory myopathies
, , Featured, News, Research
We are excited to announce our first publication, “Pain profile and opioid medication use in patients with idiopathic inflammatory...
Join for a retrospective look at how a community call to action led to a seminal study on pain...
Myositis patients and caregivers are invited to participate in a survey to help us understand how myositis impacts certain...
MSU is excited to welcome Abhiram R. Bhashyam, MD, Ph.D., Hand and Upper Extremity Orthopaedic Surgeon at Massachusetts General...
Intravenous Immune Globulin (IVIg) – A newly approved therapeutic option for the treatment of adult dermatomyositis
, , Featured, Myositis Treatments, Research
Watch to learn about Octapharma’s IVIg therapy and the results of the landmark Progress in Dermatomyositis (ProDERM) study. The...
Watch Poor Long-term Clinical Outcomes and Health-Related Quality of Life in Dermatomyositis and Polymyositis
, , Featured, Research
Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune inflammatory myopathies characterized by muscle weakness and multiple extra-muscular manifestations that...
MSU is hosting the first FDA Listening Session on Adult Dermatomyositis on April 26, 2022. We hope the FDA will come...
Plasma Services Group (PSG) provides an update on what your samples are being used for and how important it...
AllStripes was honored to host this webinar with the Myositis Support and Understanding Association to discuss our current and...
Seeking ten (10) people living with Dermatomyositis who would be willing to share their personal experience in a market...
Myositis Support & Understanding and AllStripes Partner for New Dermatomyositis Research
, , Dermatomyositis, Featured, Research
Myositis Support & Understanding and AllStripes are partnering to create a database that will enable new Dermatomyositis research projects!...
Get Support!
Recently posted
-
Managing Your Expectations with Movement & Exercise with Kourage Health March 3, 2025
-
Meet Elisa Glass: MSU’s First Executive Director – Vision & Journey February 17, 2025
-
Catch the Replay: “Your Health, Your Voice: Building a Lifesaving Medical Binder” with the Three Myositis Musketeers! January 23, 2025
